Skip to main content
Neuland Laboratories Limited. logo

Neuland Laboratories Limited. — Investor Relations & Filings

Ticker · NEULANDLAB ISIN · INE794A01010 LEI · 335800AVHZURTYQ17N08 BSE.NS Manufacturing
Open in API
Filings indexed 947 across all filing types
Latest filing 2018-11-05 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS NEULANDLAB

About Neuland Laboratories Limited.

https://www.neulandlabs.com

Neuland Laboratories Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and provides comprehensive Custom Manufacturing Solutions (CMS). The company focuses on complex chemistry and high-quality standards, operating state-of-the-art manufacturing facilities that comply with international regulatory requirements, including those of the USFDA and EDQM. Its product portfolio spans diverse therapeutic areas such as cardiovascular, central nervous system, anti-infectives, and antiasthmatics. Neuland supports pharmaceutical companies globally through the entire lifecycle of a drug, from early-stage clinical development to commercial-scale production. By leveraging advanced technical expertise and a robust quality management system, the organization delivers reliable chemical synthesis and process optimization services to both innovator and generic drug manufacturers.

Recent filings

Filing Released Lang Actions
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a letter from Neuland Laboratories Limited addressed to stock exchanges, referencing compliance with Regulation 47(1)(b) of SEBI Listing Regulations, 2015. It includes a newspaper publication of unaudited financial results for the quarter ended September 30, 2018. The document contains detailed financial data for the quarter and half year ended September 30, 2018, including revenue, net profit, earnings per share, and other financial metrics. The presence of unaudited financial results for a quarter and half year period indicates this is a quarterly financial report. The document is about 15,000 characters long and contains substantive financial data, not merely an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2018-11-05 English
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of Neuland Laboratories Limited's financial results for the second quarter (Q2FY19) and half-year (H1FY19) periods ending September 30, 2018. It includes comprehensive financial highlights such as revenue, EBITDA, net profit, EPS, and operational details. It also mentions an upcoming earnings call to discuss these results. The presence of quarterly financial data, year-over-year and quarter-over-quarter comparisons, and management commentary indicates this is a comprehensive interim financial report rather than a brief earnings release or a simple announcement. The document length (6516 characters) supports it being a substantive report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q2 2019
2018-11-02 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a formal communication from Neuland Laboratories Limited to stock exchanges (BSE and NSE) regarding the outcome of a Board Meeting. It specifically mentions compliance with Regulation 33 of the SEBI Listing Regulations, 2015, which pertains to the disclosure of quarterly financial results. The document includes the unaudited financial results for the quarter ended September 30, 2018, and the limited review report by the auditors. The presence of detailed financial data for the quarter and half-year, along with the auditor's review report, indicates this is a quarterly financial report. The document is about unaudited quarterly financial results and includes substantive financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2018-11-02 English
Financial Result Updates
Regulatory Filings
2018-11-02 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 90% confidence The document is an announcement of an upcoming earnings call for Neuland Laboratories Limited regarding its Q2 FY 2018-19 results. It provides details about the date, time, dial-in numbers, and background information about the company. There are no actual financial results or detailed financial statements included in the text. The document is primarily an invitation and informational notice about the earnings call, not the transcript or the earnings release itself. Therefore, it fits best as a Call Transcript (CT) category, as it relates to the earnings call event. However, since the actual transcript is not included and this is only an announcement of the call, it is more appropriate to classify it as a Regulatory Filing (RNS) because it is a general regulatory announcement about the call and results release, not the call transcript or earnings release itself.
2018-10-26 English
Press Release
Regulatory Filings Classification · 100% confidence The document text is extremely short (111 characters) and contains no substantive content, only placeholders for omitted pictures. There is no financial data, no report content, no announcements, or any textual information to classify as a specific report type. Given the lack of content, this document does not fit any specific filing category and defaults to the fallback category for miscellaneous or non-informative filings, which is Regulatory Filings (RNS).
2018-10-26 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.